Key result
No clinical study data is present in the provided text, which consists only of journal editorial board information.
Why the study?
Does prophylactic low-molecular-weight-heparin improve quality-adjusted life years and cost-effectiveness in ambulatory cancer patients with no VTE history?
Population
Ambulatory cancer patients with no VTE history and no indication for prophylactic or therapeutic…
Comparison
Prophylactic low-molecular-weight-heparin given… vs No anticoagulation
Design
Other
Follow-up
24 months (modeled)
Authors
Loading...
No data inform LMWH prophylaxis decisions; leaves open cost-effectiveness pending randomized confirmation of mortality benefit.
Does prophylactic low-molecular-weight-heparin improve quality-adjusted life years and cost-effectiveness in ambulatory cancer patients with no VTE history?
Prophylactic LMWH in ambulatory cancer patients without conventional indications appears economically reasonable if its suggested mortality benefit is confirmed in future trials.
Pishko et al. (2012) studied this question. No clinical study data is present in the provided text, which consists only of journal editorial board information.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: